{
    "clinical_study": {
        "@rank": "127761", 
        "arm_group": [
            {
                "arm_group_label": "PCC group", 
                "arm_group_type": "Experimental", 
                "description": "Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm."
            }, 
            {
                "arm_group_label": "FFP group", 
                "arm_group_type": "Active Comparator", 
                "description": "Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to find out if the regimen of prothrombin complex concentrate\n      (PCC) together with fibrinogen concentrate is as efficient as fresh frozen plasma (FFP)\n      (plus fibrinogen if needed) during the early stages of the transfusion therapy in postpartum\n      haemorrhage (PPH). The original protocol included the use of HES and the recruitment of\n      patients was postponed while waiting the final decision by EMA. All HES solutions were\n      abandoned at our institution in September and an amendment was made to change the protocol.\n      HES solution are replaced by the use of hyperoncotic (20%) albumin."
        }, 
        "brief_title": "PCC and Fibrinogen Compared With FFP in PPH", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Postpartum Haemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Forty patients are randomized to receive either PCC and fibrinogen concentrate (PCC group)\n      or FFP (and fibrinogen if needed) (FFP group), 20 patients in each group. Patients in the\n      PCC group receive 15 IU/kg of PCC concentrate and 2 g of fibrinogen concentrate. Patients in\n      the FFP group receive 4 units of FFP. In both groups, additional fibrinogen is administered\n      (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.\n\n      Baseline blood samples will be drawn at study inclusion when the (on-going) blood loss\n      exceeds 1500 ml. The next samples will be drawn at 45 min (or immediately after the\n      administration of the study drug if later). Otherwise, the management protocol strictly\n      follows the local PPH guideline.\n\n      The primary endpoint is the amount of blood loss within the first 6 and 24 hours after\n      delivery. Secondary endpoints include the difference/similarity in the laboratory\n      determinations (ia coagulation screen, PFA-100, CAT and ROTEM)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Women who have delivered vaginally or by caesarean section with a PPH of 2000 ml (the\n        amount of blood loss: in addition to the suctioned blood, sponges, wraps, swabs, etc. are\n        carefully weighed)\n\n        Exclusion Criteria:\n\n        Women with a history of bleeding tendency or hepatic or renal insufficiency, or PPH\n        exceeding 3000 ml because in that case the initial need for fibrinogen may be even more"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910675", 
            "org_study_id": "EudraCT-2012-003128", 
            "secondary_id": "U1030N7560"
        }, 
        "intervention": [
            {
                "arm_group_label": "PCC group", 
                "description": "15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.", 
                "intervention_name": "PCC", 
                "intervention_type": "Drug", 
                "other_name": "Octaplex, Riastab"
            }, 
            {
                "arm_group_label": "FFP group", 
                "description": "4 units Octaplas. Additional fibrinogen if needed.", 
                "intervention_name": "FFP", 
                "intervention_type": "Drug", 
                "other_name": "Octaplas"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "jouni.ahonen@fimnet.fi", 
                "last_name": "Jouni V. Ahonen, Ph.D., M.D.", 
                "phone": "+358504271852"
            }, 
            "facility": {
                "address": {
                    "city": "Helsinki", 
                    "country": "Finland", 
                    "state": "Uusimaa", 
                    "zip": "FI-00610"
                }, 
                "name": "Maternity Hospital, Helsinki University Central Hospital"
            }, 
            "investigator": {
                "last_name": "Jouni V. Ahonen, Ph.D., M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Use of Prothrombin Complex Concentrate and Fibrinogen Compared With Fresh Frozen Plasma (and Fibrinogen if Needed) in the Treatment of Postpartum Haemorrhage", 
        "overall_contact": {
            "email": "jouni.ahonen@fimnet.fi", 
            "last_name": "Jouni V. Ahonen, Ph. D., M.D.", 
            "phone": "+358504271852"
        }, 
        "overall_official": {
            "affiliation": "Maternity Hospital, Helsinki University Central Hospital", 
            "last_name": "Jouni V. Ahonen, Ph.D., M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The suctioned blood is recorded and sponges, wraps, swabs, etc. are carefully weighed. The amount of blood loss will be compared between the groups.", 
            "measure": "Blood loss", 
            "safety_issue": "No", 
            "time_frame": "Within the first 6 and 24 hours after delivery"
        }, 
        "reference": {
            "PMID": "21069897", 
            "citation": "Ahonen J, Stefanovic V, Lassila R. Management of post-partum haemorrhage. Acta Anaesthesiol Scand. 2010 Nov;54(10):1164-78. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910675"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Helsinki University Central Hospital", 
            "investigator_full_name": "Jouni Ahonen", 
            "investigator_title": "Consultant anaesthesiologist, M.D., Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "INTEM, EXTEM, FIBTEM and APTEM / ROTEM", 
                "measure": "Maximum clot firmness (MCF)", 
                "safety_issue": "No", 
                "time_frame": "At the time when the blood loss exceeds 1500 ml and 45 min later"
            }, 
            {
                "description": "CAT", 
                "measure": "Endogenous thrombin potential", 
                "safety_issue": "No", 
                "time_frame": "At the time when the blood loss exceeds 1500 ml and 45 min later"
            }, 
            {
                "description": "Clauss method", 
                "measure": "Fibrinogen level", 
                "safety_issue": "No", 
                "time_frame": "At the time when the blood loss exceeds 1500 ml and 45 min later"
            }, 
            {
                "description": "PFA-100", 
                "measure": "Platelet function", 
                "safety_issue": "No", 
                "time_frame": "At the time when the blood loss exceeds 1500 ml and 45 min later"
            }, 
            {
                "description": "INTEM, EXTEM, FIBTEM and APTEM / ROTEM", 
                "measure": "Clotting time (CT)", 
                "safety_issue": "No", 
                "time_frame": "At the time when the blood loss exceeds 1500 ml and 45 min later"
            }, 
            {
                "description": "INTEM, EXTEM, FIBTEM and APTEM / ROTEM", 
                "measure": "Clot formation time (CFT)", 
                "safety_issue": "No", 
                "time_frame": "At the time when the blood loss exceeds 1500 ml and 45 min later"
            }
        ], 
        "source": "Helsinki University Central Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Helsinki University Central Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}